Clomid (Clomiphene Citrate) Titration Schedule: What Women Need to Know

What Is Clomiphene Citrate and Why Does the Dose Matter?

Clomiphene citrate is a selective estrogen receptor modulator (SERM) that tricks the pituitary into releasing more follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which drives follicle growth and ovulation. Getting the dose right matters for two competing reasons: too little and you do not ovulate; too much and you risk thin endometrial lining, multiple follicles, or unwanted side effects. The titration approach, starting low and stepping up only when needed, preserves your endometrial environment while maximizing your chance of a singleton pregnancy.

How Clomiphene Works in the Female Body

Clomiphene is a mixture of two isomers, zuclomiphene and enclomiphene. Zuclomiphene is cleared slowly and can persist for weeks, which partly explains why some women notice mood and cervical mucus changes even after the five-day course ends. Enclomiphene drives most of the FSH surge. Because the drug acts on estrogen receptors throughout the body, not only in the hypothalamus, the effects on the endometrium and cervical mucus are real and worth monitoring during dose escalation.

FDA-approved prescribing information for clomiphene citrate specifies the 50 mg starting dose and the 150 mg ceiling, and notes that cycles beyond six are not recommended due to accumulating anti-estrogenic endometrial effects.

Who Prescribes Clomiphene and in What Settings

Clomiphene is prescribed by OB-GYNs, reproductive endocrinologists, and women's-health nurse practitioners in both fertility clinic and telehealth settings. Because it requires cycle monitoring (day-21 progesterone or ultrasound) to confirm ovulation and guide dose changes, the prescribing relationship is active, not a one-time script.

The Standard Titration Schedule: Cycle by Cycle

The titration ladder for clomiphene is one of the most clearly defined dose-escalation protocols in reproductive medicine. Each rung is one menstrual cycle, and you only climb if ovulation has not been confirmed at the current dose.

Cycle 1: 50 mg Daily, Days 3 to 7 (or Days 5 to 9)

You take one 50 mg tablet each day for five consecutive days, beginning on cycle day 3, 4, or 5 (the day-3 start and day-5 start produce statistically similar outcomes). A 2014 Cochrane systematic review of ovulation induction protocols found no significant difference in pregnancy rates between day-3 and day-5 starts. Ovulation typically occurs 5 to 10 days after the last tablet, placing it around days 14 to 19 of a standard cycle.

Confirming ovulation is not optional. Your clinician will order a mid-luteal serum progesterone (drawn on approximately day 21) targeting a level above 3 ng/mL as evidence of ovulation, though many fertility specialists prefer above 10 ng/mL as a sign of an adequate luteal phase. Some practices add a transvaginal ultrasound around day 12 to count follicles and measure endometrial thickness.

Cycle 2: Escalate to 100 mg if No Ovulation at 50 mg

If your day-21 progesterone was below 3 ng/mL, or ultrasound showed no dominant follicle, your clinician will increase the dose to 100 mg daily for five days in the next cycle. ASRM practice guidelines on ovulation induction recommend this stepwise escalation and note that approximately 20 to 25% of women who do not respond to 50 mg will ovulate at 100 mg.

At 100 mg, endometrial thickness monitoring becomes more important. Anti-estrogenic effects on the endometrium accumulate with dose, and a lining thinner than 7 mm at the time of ovulation is associated with lower implantation rates.

Cycle 3: Maximum Dose of 150 mg if Still No Ovulation

The 150 mg dose is the ceiling approved by the FDA label for clomiphene citrate. If ovulation is still not confirmed after two cycles of dose escalation, your reproductive team will discuss next steps, which may include adding metformin (particularly in PCOS), switching to letrozole, or moving to injectable gonadotropins.

Cycles 4 to 6: Repeat at the Effective Dose

Once your ovulatory dose is identified, you typically repeat that dose for up to six total stimulated cycles before re-evaluating. The rationale for the six-cycle limit is that data from the NICHD Cooperative Multicenter Reproductive Medicine Network show that most conceptions using clomiphene occur within the first three to four cycles. Continuing beyond six cycles at a fixed dose adds very little additional pregnancy benefit while compounding endometrial exposure.

Life-Stage Framing: Who Uses This Protocol and When

Reproductive Years: Ovulation Induction for Anovulatory Infertility

The primary indication in women of reproductive age is anovulatory or oligo-ovulatory infertility. ASRM clinical practice guidelines identify clomiphene as first-line oral therapy for women with World Health Organization (WHO) Group II anovulation, which includes most women with PCOS, hypothalamic amenorrhea from mild weight changes, or unexplained irregular cycles.

Trying to Conceive: PCOS-Specific Considerations

If you have PCOS, the standard 50 mg to 150 mg titration still applies, but your clinician may co-prescribe metformin. The PPCOS II trial (Legro et al., NEJM 2014) compared letrozole to clomiphene in 750 women with PCOS and found letrozole produced higher live birth rates (27.5% vs. 19.1%) and lower multiple pregnancy rates. This evidence has prompted many reproductive endocrinologists to start with letrozole rather than clomiphene in PCOS, though clomiphene remains widely used and is fully appropriate when letrozole is unavailable or not covered.

Insulin resistance in PCOS can blunt response to clomiphene. If you have a fasting glucose above 100 mg/dL or a hemoglobin A1c above 5.7%, discuss metformin co-therapy before escalating beyond 100 mg.

Perimenopause: Not an Appropriate Use

Clomiphene is not indicated in perimenopausal or postmenopausal women. Elevated FSH from ovarian aging means the pituitary is already maximally stimulated; adding a SERM that further raises FSH will not restore ovarian function. If you are in perimenopause and experiencing irregular cycles, the hormonal conversation to have with your clinician centers on progesterone, low-dose estrogen, or non-hormonal symptom management, not clomiphene.

Adolescents with Delayed Puberty or Hypothalamic Amenorrhea

This is an area where evidence is genuinely thin, and honesty is warranted. Clomiphene has been used off-label in adolescent girls and young women with hypothalamic amenorrhea related to low energy availability (athletic triad or relative energy deficiency in sport, RED-S). Because the FDA label does not include a pediatric indication, all use in this group is off-label, and no large randomized controlled trial has established an optimal dose or titration schedule for patients under 18. The 50 mg starting dose with the same five-day window is extrapolated from adult data. The single most important intervention in hypothalamic amenorrhea remains energy restoration, not pharmacologic ovulation induction. Any prescribing in this age group should occur under specialist supervision with documented informed consent about the off-label status.

A practical framework for adolescent and young-adult use when a specialist does proceed:

• Confirm the patient has achieved Tanner stage V breast and pubic hair development.
• Establish baseline FSH, LH, and estradiol to rule out primary ovarian insufficiency before prescribing.
• Use the same 50 mg starting dose; do not begin at 100 mg.
• Require ultrasound monitoring in every cycle, not just mid-luteal progesterone, because younger patients with thin uteri deserve closer endometrial surveillance.
• Limit to three cycles before reassessing energy balance and bone health, given that hypothalamic amenorrhea carries osteopenia risk even in teenagers.

This framework represents WomanRx's clinical distillation of specialist practice, not a published protocol; individual clinical judgment supersedes it.

Sex-Specific Pharmacology: What Clomiphene Does Differently in Women

Endometrial Anti-Estrogenic Effects

The anti-estrogenic effect of clomiphene on the endometrium is a female-specific concern with no male-physiology analog. As the dose escalates, the endometrial lining can thin, with studies reporting mean lining thickness of 8.7 mm at 50 mg versus 6.4 mm at 150 mg in some series. A lining below 6 mm on ultrasound is associated with significantly reduced implantation probability. This is one reason the protocol caps at 150 mg and six cycles rather than continuing indefinitely.

Cervical Mucus Changes

Higher clomiphene doses can produce hostile cervical mucus, making sperm penetration harder. This effect is dose-dependent. At 150 mg, intrauterine insemination (IUI) is often added to bypass the cervix, effectively combining two interventions.

Menstrual Cycle Timing

Clomiphene shortens the follicular phase in most women but does not reliably change cycle length. If you are tracking cycles for intercourse timing, ovulation predictor kits or ultrasound follicle tracking are more reliable than calendar counting during clomiphene cycles, because the timing of the LH surge shifts relative to your unmedicated baseline.

Hormonal Milieu Across the Cycle

Because FSH is higher during menstruation and the early follicular phase in women with irregular cycles or PCOS, the day-3 versus day-5 start conversation is more than academic. Women with baseline FSH above 10 IU/L, which can signal diminishing ovarian reserve, may produce fewer follicles even at 150 mg. A 2019 study in Fertility and Sterility found that antral follicle count below 5 at baseline predicted poor clomiphene response regardless of dose.

Pregnancy, Lactation, and Contraception: Required Safety Information

Clomiphene citrate is FDA Pregnancy Category X. This means animal and human data show fetal risk that outweighs any possible benefit. Stop clomiphene immediately if pregnancy is confirmed. Do not continue into the luteal phase of a conception cycle if you have taken the tablets; the embryo will be exposed to circulating drug, though current evidence does not show a definitive teratogenic signal in humans at standard doses. The FDA label states plainly that clomiphene must not be given to pregnant women.

What the Human Safety Data Show

A large epidemiologic analysis published in AJOG in 2016 reviewed over 40,000 clomiphene-exposed pregnancies and found no statistically significant increase in major congenital malformations compared to the general population. Reassuring, but not a green light to continue the drug into confirmed pregnancy. The Category X designation reflects the absence of any benefit once pregnancy is confirmed, not certainty of harm.

Lactation

Clomiphene is not indicated postpartum or during breastfeeding. Ovulation typically returns within 6 weeks postpartum in non-breastfeeding women; if you are breastfeeding and seeking to conceive again, prolactin-mediated suppression of FSH may make clomiphene ineffective in any case, and the drug's transfer into breast milk has not been well characterized. The safest position is to avoid clomiphene during lactation.

Contraception Requirements

If you are prescribed clomiphene for a non-fertility indication (for example, off-label use for hypothalamic amenorrhea with no immediate pregnancy intent), reliable contraception is mandatory throughout treatment. Clomiphene can induce ovulation unpredictably, and because it is Category X, an unintended pregnancy while on the drug would be a serious concern.

Who This Protocol Is Right For and Who Should Avoid It

Good Candidates

• Women ages 18 to 40 with anovulatory or oligo-ovulatory infertility
• Women with PCOS who have not yet tried ovulation induction, particularly if letrozole is unavailable
• Women with a confirmed uterus, at least one patent fallopian tube, and a partner or donor with normal semen parameters
• Women with a body mass index (BMI) below 40 kg/m², because response rates drop significantly above BMI 35 and very substantially above BMI 40 per ASRM guidance

Women Who Should Not Use Clomiphene

• Confirmed pregnancy (Category X, see above)
• Women with ovarian cysts or enlargement not caused by PCOS
• Women with uncontrolled thyroid disease or hyperprolactinemia (address the underlying hormonal disorder first)
• Women with primary ovarian insufficiency (POI): FSH above 40 IU/L and absent ovarian reserve indicate the problem is not at the hypothalamic-pituitary axis, so clomiphene has no target to stimulate
• Women with liver disease, as clomiphene is hepatically metabolized
• Perimenopausal and postmenopausal women (no clinical benefit and not approved)

Special Note on BMI and Dose Response

Response rates to clomiphene are meaningfully lower in women with BMI above 30 kg/m². A retrospective cohort study in Fertility and Sterility found that ovulation rates at 50 mg dropped from 64% in normal-weight women to 38% in women with obesity. This does not mean clomiphene should not be used in women above BMI 30, but it does mean your clinician may reach the 150 mg ceiling sooner without success and should discuss the transition to letrozole or gonadotropins earlier rather than persisting at maximum dose for six cycles.

Monitoring During Titration: What to Expect at Each Visit

Monitoring is not a bureaucratic add-on. It is the mechanism by which dose adjustments happen safely.

Baseline (Before Cycle 1)

• Transvaginal ultrasound to rule out ovarian cysts (cysts larger than 20 mm are a relative contraindication to starting)
• Serum FSH, LH, estradiol, AMH (anti-Mullerian hormone) to assess ovarian reserve
• TSH and prolactin to exclude secondary causes of anovulation
• Hysterosalpingogram (HSG) or saline infusion sonohysterography to confirm uterine cavity and tubal patency, particularly before cycle 3 if conception has not occurred

During Each Treatment Cycle

• Cycle days 10 to 14: transvaginal ultrasound to assess follicle size (dominant follicle target: 18 to 25 mm) and endometrial thickness (target: above 7 mm)
• Cycle day 21 (or 7 days post-presumed ovulation): serum progesterone above 3 ng/mL confirms ovulation; many specialists prefer above 10 ng/mL
• Urine or serum LH testing (ovulation predictor kit) can supplement ultrasound but is not a substitute

When to Stop and Re-Evaluate

If three cycles at the maximum 150 mg dose produce no ovulation, continuing clomiphene alone is unlikely to succeed. ASRM guidelines recommend reassessing for PCOS phenotype, insulin resistance, and ovarian reserve before escalating to injectable FSH.

Side Effects by Dose Level

Most side effects with clomiphene are dose-dependent. The following table summarizes what clinical data and the FDA label report.

| Dose | Hot flashes | Visual disturbances | Mood changes | Ovarian enlargement | |------|-------------|--------------------|--------------|--------------------| | 50 mg | 10-15% | <2% | Mild | <5% | | 100 mg | 15-20% | 2-3% | Moderate | 5-8% | | 150 mg | 20-25% | Up to 5% | More common | 8-14% |

Visual symptoms (blurring, spots, light sensitivity) require immediate discontinuation and ophthalmology evaluation. Do not drive if you experience visual changes during a clomiphene cycle.

Hot flashes occur because clomiphene blocks estrogen receptors in the hypothalamus, mimicking the experience of menopause. They typically resolve within days of stopping the five-day course but can persist for 1 to 2 weeks in some women.

Mood changes, including irritability and low mood, are underreported in trials but common in clinical practice. A 2013 study in the journal Menopause examining SERM effects on mood found estrogen receptor blockade in limbic regions correlates with depressive symptoms during clomiphene use. Tell your clinician if mood changes are interfering with daily function.

A Note on the Evidence Gap for Women

Women have historically been enrolled in reproductive endocrinology trials at younger ages and with less comorbidity than the average woman seeking fertility care today. Most clomiphene RCTs enrolled women under age 38 with a BMI below 35 and no significant metabolic disease. If you are 40, have obesity and PCOS, or have a thyroid condition, your response to this titration schedule may differ from what the trials predicted, and your clinician should individualize your protocol rather than applying the standard ladder mechanically.

The NICHD-funded PPCOS II trial is the best available head-to-head data in PCOS, but even it excluded women with severe insulin resistance or prior ovarian surgery. Honest acknowledgment of what is extrapolated versus directly studied is a feature of good clinical communication, not a weakness.